Lifecore Biomedical (NASDAQ:LFCR) Upgraded to Outperform at Barrington Research

Barrington Research upgraded shares of Lifecore Biomedical (NASDAQ:LFCR) from a market perform rating to an outperform rating in a research report sent to investors on Tuesday morning, Marketbeat.com reports. The firm currently has $5.50 target price on the stock.

Several other equities analysts have also recently commented on the stock. Zacks Research raised shares of Lifecore Biomedical to a “hold” rating in a research report on Thursday, January 1st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Lifecore Biomedical in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Lifecore Biomedical presently has an average rating of “Hold” and an average price target of $5.50.

Lifecore Biomedical Stock Performance

Shares of LFCR stock opened at $4.36 on Tuesday. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.80 and a quick ratio of 1.67. The firm has a 50-day moving average of $7.47 and a 200-day moving average of $7.46. Lifecore Biomedical has a one year low of $4.09 and a one year high of $8.98. The company has a market cap of $163.37 million, a P/E ratio of -4.45 and a beta of 0.62.

Lifecore Biomedical (NASDAQ:LFCR) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.05). Lifecore Biomedical had a negative return on equity of 1,211.09% and a negative net margin of 23.08%.The firm had revenue of $35.75 million for the quarter, compared to analysts’ expectations of $35.31 million. Equities research analysts forecast that Lifecore Biomedical will post -0.91 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Millennium Management LLC raised its holdings in shares of Lifecore Biomedical by 86.2% in the 4th quarter. Millennium Management LLC now owns 251,705 shares of the company’s stock worth $2,059,000 after purchasing an additional 116,500 shares during the period. AQR Capital Management LLC grew its holdings in Lifecore Biomedical by 28.4% during the fourth quarter. AQR Capital Management LLC now owns 16,171 shares of the company’s stock valued at $132,000 after purchasing an additional 3,574 shares during the period. Jump Financial LLC bought a new position in Lifecore Biomedical during the fourth quarter valued at $123,000. Price T Rowe Associates Inc. MD increased its position in Lifecore Biomedical by 20.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,646 shares of the company’s stock worth $137,000 after buying an additional 2,826 shares during the last quarter. Finally, State of Wisconsin Investment Board increased its position in Lifecore Biomedical by 138.2% in the fourth quarter. State of Wisconsin Investment Board now owns 37,825 shares of the company’s stock worth $309,000 after buying an additional 21,946 shares during the last quarter. 83.36% of the stock is owned by institutional investors.

Key Headlines Impacting Lifecore Biomedical

Here are the key news stories impacting Lifecore Biomedical this week:

• Positive Sentiment: Barrington Research upgraded Lifecore from “market perform” to “outperform” and set a $5.50 price target (~26% upside vs. the current price), which can attract buyers and help support the stock. Barrington Research Upgrade
• Positive Sentiment: Company press release and filings show recorded fourth-quarter revenues of $35.7M and transition-period revenues of $75.5M, plus multiple new programs signed (including commercial site transfers) and initiatives to improve margins — fundamentals that support medium-term growth expectations. Company Press Release
• Positive Sentiment: Management is targeting a ~12% revenue CAGR through 2029, signaling an organized growth plan and setting investor expectations for sustained topline expansion (though execution risk remains). Seeking Alpha: Growth Target
• Neutral Sentiment: Q4 results were mixed: revenue slightly beat consensus ($35.75M vs. $35.31M) but EPS missed (loss of $0.16 vs. consensus -$0.11). Investors will parse whether margin improvements and new program wins offset near-term profitability weakness. Conference call transcript, press release and slide deck available for detail. Earnings Details & Call
• Negative Sentiment: A shareholder firm (Johnson Fistel) announced an investigation into potential claims involving Lifecore executives, which introduces legal risk and could pressure sentiment until resolved. Shareholder Investigation

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.